

# Pei Hui

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/615290/publications.pdf>

Version: 2024-02-01

111  
papers

3,928  
citations

117625

34  
h-index

144013

57  
g-index

117  
all docs

117  
docs citations

117  
times ranked

4969  
citing authors

#	ARTICLE	IF	CITATIONS
1	Endometrial Polyp in Postmenopausal Women: An Epicenter for the Development of Endometrial Serous Carcinoma. <i>Archives of Pathology and Laboratory Medicine</i> , 2023, 147, 413-417.	2.5	1
2	Clinicopathologic characteristics and oncologic outcomes in adenosarcoma of gynecologic sites. <i>Gynecologic Oncology Reports</i> , 2022, 39, 100913.	0.6	2
3	Randomised phase II trial of weekly ixabepilone±biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer. <i>British Journal of Cancer</i> , 2022, 126, 1695-1703.	6.4	5
4	A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability. <i>Cancer</i> , 2022, 128, 1206-1218.	4.1	28
5	SalivISION: a rapid saliva-based COVID-19 screening and diagnostic test with high sensitivity and specificity. <i>Scientific Reports</i> , 2022, 12, 5729.	3.3	6
6	Significance of KRAS mutation testing in biliary brushing cytology specimens: A 10-year retrospective review. <i>Cancer Cytopathology</i> , 2022, 130, 558-565.	2.4	2
7	Combining genomic and epidemiological data to compare the transmissibility of SARS-CoV-2 variants Alpha and Iota. <i>Communications Biology</i> , 2022, 5, 439.	4.4	9
8	Port-Site Metastasis in Gynecological Malignancies. <i>Journal of the Society of Laparoendoscopic Surgeons</i> , 2021, 25, e2020.00081.	1.1	4
9	Prognostic Assessment of BRAF Mutation in Preoperative Thyroid Fine-Needle Aspiration Specimens. <i>American Journal of Clinical Pathology</i> , 2021, 156, 100-108.	0.7	1
10	Reproducibility of scoring criteria for HER2 immunohistochemistry in endometrial serous carcinoma: a multi-institutional interobserver agreement study. <i>Modern Pathology</i> , 2021, 34, 1194-1202.	5.5	24
11	SalivaDirect: A simplified and flexible platform to enhance SARS-CoV-2 testing capacity. <i>Med</i> , 2021, 2, 263-280.e6.	4.4	211
12	Integrated mutational landscape analysis of uterine leiomyosarcomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	48
13	Detection of cytogenomic abnormalities by OncoScan microarray assay for products of conception from formalin-fixed paraffin-embedded and fresh fetal tissues. <i>Molecular Cytogenetics</i> , 2021, 14, 21.	0.9	1
14	Early introductions and transmission of SARS-CoV-2 variant B.1.1.7 in the United States. <i>Cell</i> , 2021, 184, 2595-2604.e13.	28.9	113
15	Potential role of IFN-λ in COVID-19 patients and its underlying treatment options. <i>Applied Microbiology and Biotechnology</i> , 2021, 105, 4005-4015.	3.6	25
16	Multiplex qPCR discriminates variants of concern to enhance global surveillance of SARS-CoV-2. <i>PLoS Biology</i> , 2021, 19, e3001236.	5.6	200
17	Genotyping diagnosis of gestational trophoblastic disease: frontiers in precision medicine. <i>Modern Pathology</i> , 2021, 34, 1658-1672.	5.5	17
18	Complete Hydatidiform Mole and Coexisting Fetus With Gastroschisis: A Case Report Highlighting the Importance of Diagnostic Genotyping. <i>Pediatric and Developmental Pathology</i> , 2021, 24, 575-580.	1.0	2

#	ARTICLE	IF	CITATIONS
19	DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo. <i>Gynecologic Oncology</i> , 2021, 163, 334-341.	1.4	10
20	Increased Detection of Mycobacterium tuberculosis Disease Using a Tissue-Based Laboratory-Developed Polymerase Chain Reaction Assay Compared to Standard Diagnostics. <i>American Journal of Tropical Medicine and Hygiene</i> , 2021, 105, 1657-1661.	1.4	0
21	Minimal uterine serous carcinoma and endometrial polyp: a close clinicopathological relationship. <i>Human Pathology</i> , 2021, 118, 1-8.	2.0	6
22	Classifying Anal Intraepithelial Neoplasia 2 Based on LAST Recommendations. <i>American Journal of Clinical Pathology</i> , 2021, 155, 845-852.	0.7	8
23	Does Specimen Type Have an Impact on HER2 Status in Endometrial Serous Carcinoma? Discordant HER2 Status of Paired Endometrial Biopsy and Hysterectomy Specimens in the Presence of Frequent Intratumoral Heterogeneity. <i>International Journal of Gynecological Pathology</i> , 2021, 40, 263-271.	1.4	16
24	A Timely Update of Immunohistochemistry and Molecular Classification in the Diagnosis and Risk Assessment of Endometrial Carcinomas. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 1367-1378.	2.5	7
25	SARS-CoV-2 expresses a microRNA-like small RNA able to selectively repress host genes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	52
26	HER2 testing of gynecologic carcinosarcomas: tumor stratification for potential targeted therapy. <i>Modern Pathology</i> , 2020, 33, 118-127.	5.5	53
27	Sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo. <i>Molecular Oncology</i> , 2020, 14, 645-656.	4.6	20
28	In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma. <i>Gynecologic Oncology</i> , 2020, 156, 430-438.	1.4	18
29	Lack of genetic homozygosity in prepubertal teratomas: divergent pathogenesis distinct from that of teratomas in adolescents. <i>Laboratory Investigation</i> , 2020, 100, 1447-1454.	3.7	4
30	Germline NLRP7 mutations: genomic imprinting and a hydatidiform mole. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 477, 175-176.	2.8	0
31	Heterozygous/dispermic complete mole confers a significantly higher risk for post-molar gestational trophoblastic disease. <i>Modern Pathology</i> , 2020, 33, 1979-1988.	5.5	20
32	Molecular and clinicopathologic characterization of intravenous leiomyomatosis. <i>Modern Pathology</i> , 2020, 33, 1844-1860.	5.5	16
33	Genital tuberculosis screening at an academic fertility center in the United States. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 223, 737.e1-737.e10.	1.3	17
34	Selection of HER2/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma. <i>Gynecologic Oncology Reports</i> , 2020, 32, 100554.	0.6	3
35	Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 118.	2.8	30
36	Randomized Phase II Trial of Carboplatin+Paclitaxel Compared with Carboplatin+Paclitaxel+Trastuzumab in Advanced (Stage III+IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis. <i>Clinical Cancer Research</i> , 2020, 26, 3928-3935.	7.0	154

#	ARTICLE	IF	CITATIONS
37	Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan. <i>Scientific Reports</i> , 2020, 10, 973.	3.3	31
38	Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas. <i>Oncotarget</i> , 2020, 11, 560-570.	1.8	32
39	Adjuvant Hormonal Therapy for Low-Grade Endometrial Stromal Sarcoma. <i>Reproductive Sciences</i> , 2019, 26, 600-608.	2.5	14
40	Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 22730-22736.	7.1	52
41	Inverted duplication, triplication and quintuplication through sequential breakage- <i>fusion</i> -bridge events induced by a terminal deletion at 5p in a case of spontaneous abortion. <i>Molecular Genetics &amp; Genomic Medicine</i> , 2019, 7, e00965.	1.2	5
42	Prognostic markers for immunodeficiency-associated primary central nervous system lymphoma. <i>Journal of Neuro-Oncology</i> , 2019, 144, 107-115.	2.9	22
43	Precision genotyping diagnosis of lung tumors with trophoblastic morphology in young women. <i>Modern Pathology</i> , 2019, 32, 1271-1280.	5.5	17
44	Paternal uniparental isodisomy of tyrosine hydroxylase locus at chromosome 11p15.4: spectrum of phenotypical presentations simulating hydatidiform moles. <i>Modern Pathology</i> , 2019, 32, 1180-1188.	5.5	15
45	Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 619-624.	7.1	49
46	Ten-Year Comparison Study of Type 1 and 2 Endometrial Cancers: Risk Factors and Outcomes. <i>Gynecologic and Obstetric Investigation</i> , 2019, 84, 290-297.	1.6	27
47	Gestational Trophoblastic Tumors: A Timely Review of Diagnostic Pathology. <i>Archives of Pathology and Laboratory Medicine</i> , 2019, 143, 65-74.	2.5	60
48	Minimal microsatellite shift in microsatellite instability high endometrial cancer: a significant pitfall in diagnostic interpretation. <i>Modern Pathology</i> , 2019, 32, 650-658.	5.5	37
49	Practical applications of DNA genotyping in diagnostic pathology. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 175-188.	3.1	9
50	MicroRNA signatures discriminate between uterine and ovarian serous carcinomas. <i>Human Pathology</i> , 2018, 76, 133-140.	2.0	11
51	<i>In Vitro</i> and <i>In Vivo</i> Activity of IMGN853, an Antibody-Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1003-1011.	4.1	25
52	Associated characteristics and impact on recurrence and survival of free-floating tumor fragments in the lumen of fallopian tubes in Type I and Type II endometrial cancer. <i>Gynecologic Oncology Reports</i> , 2018, 23, 28-33.	0.6	4
53	KRAS mutation of extraovarian implants of serous borderline tumor: prognostic indicator for adverse clinical outcome. <i>Modern Pathology</i> , 2018, 31, 350-357.	5.5	7
54	Hormone producing gynecological tumors: pathologic entities and clinical significance. <i>Expert Review of Endocrinology and Metabolism</i> , 2018, 13, 9-24.	2.4	0

#	ARTICLE	IF	CITATIONS
55	Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu. <i>Journal of Clinical Oncology</i> , 2018, 36, 2044-2051.	1.6	313
56	Frontiers in Gynecologic Pathology. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 1457-1458.	2.5	0
57	Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 4845-4853.	7.0	18
58	Biomarker P16 predicts progression risk of anal low-grade squamous intraepithelial lesions. <i>Aids</i> , 2018, 32, 2309-2316.	2.2	8
59	Hydatidiform Moles: Genetic Basis and Precision Diagnosis. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2017, 12, 449-485.	22.4	91
60	SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression. <i>Gynecologic Oncology</i> , 2017, 146, 179-186.	1.4	37
61	Pathologic Characteristics, Natural History, and Prognostic Implications of <i>BRAF</i> <sup>V600E</sup> Mutation in Pediatric Papillary Thyroid Carcinoma. <i>Pediatric and Developmental Pathology</i> , 2017, 20, 206-212.	1.0	26
62	Isolated port site recurrence of node-negative clinical stage IB1 cervical adenocarcinoma. <i>Gynecologic Oncology Reports</i> , 2017, 20, 54-57.	0.6	5
63	Polymerase $\beta$ (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro. <i>Gynecologic Oncology</i> , 2017, 144, 146-152.	1.4	55
64	Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression. <i>Gynecologic Oncology</i> , 2017, 147, 145-152.	1.4	18
65	Immunohistochemistry in Gynecologic Pathology: An Example-Based Practical Update. <i>Archives of Pathology and Laboratory Medicine</i> , 2017, 141, 1052-1071.	2.5	20
66	SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression. <i>Clinical Cancer Research</i> , 2017, 23, 5836-5845.	7.0	51
67	Frequent homozygosity in both mature and immature ovarian teratomas: a shared genetic basis of tumorigenesis. <i>Modern Pathology</i> , 2017, 30, 1467-1475.	5.5	22
68	SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/neu expression.. <i>Journal of Clinical Oncology</i> , 2017, 35, e14009-e14009.	1.6	1
69	Mucinous epithelial tumours arising from ovarian mature teratomas: a tissue genotyping study. <i>Histopathology</i> , 2016, 69, 383-392.	2.9	13
70	Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 12238-12243.	7.1	181
71	SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1900-1909.	4.1	55
72	Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo. <i>British Journal of Cancer</i> , 2016, 115, 303-311.	6.4	27

#	ARTICLE	IF	CITATIONS
73	Mismatch repair deficiency testing in clinical practice. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 591-604.	3.1	66
74	Congenital nevi versus metastatic melanoma in a newborn to a mother with malignant melanoma—diagnosis supported by sex chromosome analysis and Imaging Mass Spectrometry. <i>Journal of Cutaneous Pathology</i> , 2015, 42, 757-764.	1.3	21
75	Grading of atypia in genital skin lesions: routine microscopic evaluation and use of p16 immunostaining. <i>Journal of Cutaneous Pathology</i> , 2015, 42, 519-526.	1.3	5
76	Diagnostic application of KRAS mutation testing in uterine microglandular proliferations. <i>Human Pathology</i> , 2015, 46, 1000-1005.	2.0	11
77	Heterozygous bone marrow in a homozygous mature ovarian teratoma: a challenge to the germ cell theory or incidental somatic heterotopia?. <i>Journal of Clinical Pathology</i> , 2015, 68, 666-669.	2.0	2
78	KRAS mutation testing in clinical practice. <i>Expert Review of Molecular Diagnostics</i> , 2015, 15, 375-384.	3.1	20
79	Endoscopic ultrasound-guided fine-needle aspiration biopsy of autoimmune pancreatitis: diagnostic clues and pitfalls. <i>Journal of the American Society of Cytopathology</i> , 2015, 4, 211-217.	0.5	12
80	Review of Leiomyoma Variants. <i>American Journal of Roentgenology</i> , 2015, 205, 912-921.	2.2	71
81	Frequent KRAS mutation in complex mucinous epithelial lesions of the endometrium. <i>Modern Pathology</i> , 2014, 27, 675-680.	5.5	39
82	Egg Donor Pregnancy. <i>International Journal of Gynecological Pathology</i> , 2014, 33, 507-510.	1.4	18
83	Genotyping Diagnosis of Nongestational Choriocarcinoma Involving Fallopian Tube and Broad Ligament. <i>International Journal of Gynecological Pathology</i> , 2014, 33, 58-63.	1.4	14
84	Tissue identity testing of cancer by short tandem repeat polymorphism: pitfalls of interpretation in the presence of microsatellite instability. <i>Human Pathology</i> , 2014, 45, 549-555.	2.0	23
85	Ancillary Techniques to Refine Diagnosis of GTD. <i>Current Obstetrics and Gynecology Reports</i> , 2014, 3, 65-75.	0.8	0
86	Immunohistochemistry and other ancillary techniques in the diagnosis of gestational trophoblastic diseases. <i>Seminars in Diagnostic Pathology</i> , 2014, 31, 223-232.	1.5	38
87	Best practice of BRAF V600E mutation testing for the diagnosis and management of thyroid cancers. <i>Expert Review of Endocrinology and Metabolism</i> , 2014, 9, 571-577.	2.4	0
88	Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice. <i>Modern Pathology</i> , 2013, 26, 1605-1612.	5.5	125
89	Partial Hydatidiform Mole. <i>International Journal of Gynecological Pathology</i> , 2013, 32, 307-315.	1.4	50
90	Marked heterogeneity of <i>HER2/NEU</i> gene amplification in endometrial serous carcinoma. <i>Genes Chromosomes and Cancer</i> , 2013, 52, 1178-1186.	2.8	56

#	ARTICLE	IF	CITATIONS
91	Molecular pathology as the driving force for personalized oncology. Expert Review of Molecular Diagnostics, 2012, 12, 811-813.	3.1	8
92	Next Generation Sequencing: Chemistry, Technology and Applications. Topics in Current Chemistry, 2012, 336, 1-18.	4.0	40
93	BRAFmutation testing in clinical practice. Expert Review of Molecular Diagnostics, 2012, 12, 127-138.	3.1	39
94	Prognostic factors and treatment-related outcomes in patients with uterine serous cancer (USC).. Journal of Clinical Oncology, 2012, 30, 5099-5099.	1.6	0
95	Demographics of uterine serous cancer (USC) patients: A single institutional experience.. Journal of Clinical Oncology, 2012, 30, e15581-e15581.	1.6	0
96	Urinary hCG Screening in the Gynecologic Oncology Population. Journal of Gynecologic Surgery, 2011, 27, 143-146.	0.1	0
97	Precise DNA Genotyping Diagnosis of Hydatidiform Mole. Obstetrics and Gynecology, 2010, 115, 784-794.	2.4	62
98	Molecular diagnosis of gestational trophoblastic disease. Expert Review of Molecular Diagnostics, 2010, 10, 1023-1034.	3.1	26
99	Anaplastic oligoastrocytoma in Turcot syndrome. Journal of Neuro-Oncology, 2009, 95, 293-298.	2.9	9
100	Epithelioid trophoblastic tumor: comparative genomic hybridization and diagnostic DNA genotyping. Modern Pathology, 2009, 22, 232-238.	5.5	36
101	Genotypic Analysis of Hydatidiform Mole: An Accurate and Practical Method of Diagnosis. American Journal of Surgical Pathology, 2008, 32, 445-451.	3.7	81
102	Absence of Y chromosome in human placental site trophoblastic tumor. Modern Pathology, 2007, 20, 1055-1060.	5.5	32
103	Epithelioid trophoblastic tumor: clinicopathological features with an emphasis on uterine cervical involvement. Modern Pathology, 2006, 19, 75-82.	5.5	102
104	Gestational Trophoblastic Diseases. Advances in Anatomic Pathology, 2005, 12, 116-125.	4.3	71
105	HMGA proteins in malignant peripheral nerve sheath tumor and synovial sarcoma: preferential expression of HMGA2 in malignant peripheral nerve sheath tumor. Modern Pathology, 2005, 18, 1519-1526.	5.5	14
106	Recurrent endometrial stromal tumors with smooth-muscle differentiation and a protracted clinical course. Nature Clinical Practice Oncology, 2005, 2, 588-593.	4.3	2
107	Minimal uterine serous carcinoma: a clinicopathological study of 40 cases. Modern Pathology, 2005, 18, 75-82.	5.5	158
108	Comparative genomic hybridization study of placental site trophoblastic tumour: a report of four cases. Modern Pathology, 2004, 17, 248-251.	5.5	29

#	ARTICLE	IF	CITATIONS
109	Real-time Quantitative RT-PCR of Cyclin D1 mRNA in Mantle Cell Lymphoma: Comparison with FISH and Immunohistochemistry. <i>Leukemia and Lymphoma</i> , 2003, 44, 1385-1394.	1.3	36
110	Clonal analysis of cutaneous fibrous histiocytoma (dermatofibroma). <i>Journal of Cutaneous Pathology</i> , 2002, 29, 385-389.	1.3	44
111	Pathogenesis of Placental Site Trophoblastic Tumor May Require the Presence of a Paternally Derived X Chromosome. <i>Laboratory Investigation</i> , 2000, 80, 965-972.	3.7	39